• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[仅手术治疗?膀胱癌的多模式治疗]

[Surgery only? Multimodal treatment for urothelial carcinoma of the bladder].

作者信息

Schuettfort Victor, Shariat Shahrokh F, Rink Michael

机构信息

Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Urologie, Hamburg.

Allgemeines Krankenhaus der Stadt Wien-Klinikum der Medizinischen Universität Wien, Univ. Klinik für Urologie, Wien.

出版信息

Aktuelle Urol. 2020 Aug;51(4):353-362. doi: 10.1055/a-1146-2938. Epub 2020 Apr 14.

DOI:10.1055/a-1146-2938
PMID:32289833
Abstract

Radical cystectomy is the gold standard in treatment of muscle invasive bladder carcinoma. Especially for patients with advanced tumours, multimodal therapies play an important role in optimising patient care. In older patients with multiple comorbidities, who are not eligible for surgery, alternative treatment modalities are needed as well. This article summarises the current literature on multimodal treatment options in a neoadjuvant and adjuvant setting and analyses alternative potentially curative treatments. The article also summarises the initial results using checkpoint inhibitors in a multimodal treatment setting.

摘要

根治性膀胱切除术是治疗肌层浸润性膀胱癌的金标准。特别是对于晚期肿瘤患者,多模式治疗在优化患者护理方面发挥着重要作用。对于有多种合并症且不适合手术的老年患者,也需要其他治疗方式。本文总结了新辅助和辅助治疗环境下多模式治疗方案的当前文献,并分析了其他潜在的根治性治疗方法。本文还总结了在多模式治疗环境中使用检查点抑制剂的初步结果。

相似文献

1
[Surgery only? Multimodal treatment for urothelial carcinoma of the bladder].[仅手术治疗?膀胱癌的多模式治疗]
Aktuelle Urol. 2020 Aug;51(4):353-362. doi: 10.1055/a-1146-2938. Epub 2020 Apr 14.
2
Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma.肌层浸润性膀胱癌和上尿路尿路上皮癌患者化疗与手术的最佳时机
Urol Clin North Am. 2018 May;45(2):155-167. doi: 10.1016/j.ucl.2017.12.002. Epub 2018 Feb 21.
3
Perioperative chemotherapy in advanced bladder cancer: part I. Neoadjuvant treatment.晚期膀胱癌的围手术期化疗:第一部分。新辅助治疗。
Onkologie. 2003 Aug;26(4):361-5. doi: 10.1159/000072097.
4
Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histologic subtype matter?辅助化疗对根治性膀胱切除术治疗肌层浸润性膀胱癌伴不良特征和变异组织学患者的影响:组织学亚型重要吗?
Cancer. 2019 May 1;125(9):1449-1458. doi: 10.1002/cncr.31952. Epub 2019 Jan 8.
5
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.机器人辅助与开放性根治性膀胱切除术在接受围手术期化疗的肌层浸润性膀胱癌患者中的比较:多中心研究中肿瘤学家的观点。
Eur Urol Focus. 2018 Dec;4(6):937-945. doi: 10.1016/j.euf.2017.03.011. Epub 2017 Mar 31.
6
Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.膀胱移行细胞癌根治性膀胱切除术的结果及化疗效果。
Cancer. 1994 Apr 1;73(7):1926-31. doi: 10.1002/1097-0142(19940401)73:7<1926::aid-cncr2820730725>3.0.co;2-q.
7
Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology.对于具有变异组织学类型的肌层浸润性膀胱癌,在根治性膀胱切除术之前进行新辅助化疗。
Cancer. 2017 Nov 15;123(22):4346-4355. doi: 10.1002/cncr.30907. Epub 2017 Jul 25.
8
Unconventional Bladder Preservation: Factors Predicting Failure to Receive Definitive Surgery following Chemotherapy for Nonmetastatic Muscle Invasive Bladder Cancer in the National Cancer Database.非常规膀胱保留:国家癌症数据库中非转移性肌肉浸润性膀胱癌化疗后未能接受确定性手术的预测因素。
J Urol. 2018 Sep;200(3):535-540. doi: 10.1016/j.juro.2018.03.075. Epub 2018 Mar 15.
9
[Radiotherapy of urothelial carcinomas of the urinary bladder].[膀胱尿路上皮癌的放射治疗]
Urologe A. 2001 Sep;40(5):376-9. doi: 10.1007/s001200170023.
10
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.临床 T2-4N0M0 期尿路上皮膀胱癌患者新辅助化疗和根治性膀胱切除术后 1 年无复发生存的建模:Ⅱ期临床试验终点。
Eur Urol Oncol. 2019 May;2(3):248-256. doi: 10.1016/j.euo.2018.08.009. Epub 2018 Sep 7.